Johnson & Johnson has paused enrollment in a trial for an anti-tau immunotherapy, developed in partnership with AC Immune. While new patient recruitment is halted, existing participants will continue to receive dosing. This decision comes after J&J’s anti-tau asset, Posdinemab, previously failed in a Phase II Alzheimer’s study.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
J&J Pauses Enrollment In Trial Of AC Immune-Partnered Anti-Tau Immunotherapy
Johnson & Johnson has paused enrollment in a trial for an anti-tau immunotherapy, developed in partnership with AC Immune. While new patient recruitment is halted, existing participants will continue to receive dosing. This decision comes after J&J’s anti-tau asset, Posdinemab, previously failed in a Phase II Alzheimer’s study.